金斯瑞生物科技午后跌幅扩大逾11% 联营传奇生物隔夜股价大跌7%

Core Viewpoint - Kingsoft Biotech (01548) experienced a significant decline of over 11%, trading at HKD 13.41 with a transaction volume of HKD 307 million, following a drop in the stock price of its affiliate Legend Biotech by over 7% [1] Group 1: Company Performance - Legend Biotech reported a narrowed loss, with a clear growth blueprint, achieving sales of USD 1.332 billion for the first three quarters, including USD 524 million in Q3 [1] - The net loss for Legend Biotech in the first three quarters was USD 266 million, with a Q3 net loss of USD 40 million, showing significant year-on-year and quarter-on-quarter improvement [1] Group 2: Clinical Data and Market Impact - Gilead Sciences' Kite Pharma presented new clinical data for the next-generation CAR-T therapy anito-cel at the 2025 American Society of Hematology (ASH) annual meeting, demonstrating a total response rate of 96% and a complete response rate of 74%, while maintaining excellent safety [1] - The positive clinical results for anito-cel may impact the market perception of Kingsoft Biotech and its affiliate, as they compete in the CAR-T therapy space [1]